You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Point-of-care lateral flow immunoassay for diagnosis of pertussis

    SBC: DXDISCOVERY INC            Topic: NIAID

    Pertussis (Whooping cough) is a highly contagious, airborne disease that is rapidly re-emerging as a serious public health threat in the United States. Despite high vaccine coverage, annual reported cases in the U.S. have been increasing recently, with an average of 25,000 per year from 2010-2019. This is a level unseen since the early 1960s. Diagnosis of pertussis is challenging because its early ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Developing a blood fatty acid-based algorithm as an early predictor of insulin resistance: Applying machine learning to harmonized data from prospective cohort studies

    SBC: OMEGAQUANT ANALYTICS, LLC.            Topic: 200

    Project Summary Metabolic diseases, such as Metabolic Syndrome (MetSyn) and type 2 diabetes (T2DM) affect ~37% and ~10% of Americans, respectively, with a substantial impact on the health, quality of life and financial security of these individuals. Without the means to identify high risk individuals conveniently and cheaply, many will find care too little and too late: more than 80% of individual ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: 100

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Radiological Emergency Responder Field Team Route Training Simulation Using Gaming Technology and Commonly Used Atmospheric Model Outputs

    SBC: Radiation Emergency Services, LLC            Topic: NIEHS

    Project Summary Attachment In the radiological response community, with the exception of a limited number of large-scale exercises, there is a gap in technology that hinders hands-on survey training. Even when there is an available exercise, the compressed time sequence prevents realistic practice for some players, particularly field survey teams. The goal of this Phase I project is to initiate ef ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. A novel agent to manage thrombocytopenic patients with platelet transfusion refractoriness

    SBC: FIBROPLATE INC            Topic: NHLBI

    PROJECT SUMMARY Platelet Transfusion Refractoriness (PTR) or the failure to achieve the desired level of blood platelets after platelet transfusion, hampers the management of bleeding episodes in thrombocytopenic patients. PTR condition is associated with a high risk of severe bleeding complications and reduced survival rate, longer hospital stays and higher hospital costs. Existing management str ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Fibrinogen coated albumin spheres to accelerate bone healing in older adults.

    SBC: FIBROPLATE INC            Topic: NIA

    PROJECT SUMMARY Elderly people are at great risk for bone fracture and they are more likely to suffer complications during fracture healing. An inefficient healing process exposes the elderly to higher rates of delayed healing or nonunions. The slow recovery after geriatric fractures dramatically increases risks of degenerative decline, morbidity, and mortality with a negative socio-economic impac ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: OD

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with a predicted incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The 7β1 integrin is a transmembrane linkage system in skeleta ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. A multivalent, easy-to-use product to mitigate and treat radiation exposure

    SBC: FIBROPLATE INC            Topic: NIAID

    ABSTRACT The threat of radiological and nuclear accidents or attacks demands effective radiation medical countermeasures (MCM) able to mitigate and treat the effects of exposure to ionizing radiations. Hematopoietic acute radiation syndrome (HRAS) and cutaneous radiation syndrome (CRS) pose severe, life-threatening risks to exposed individuals. Currently no effective radio-mitigator (to be adminis ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. DEVELOP A COCCIDIOIDES-SPECIFIC ANTIGEN IN PATIENT SERUM OR URINE AND DEVELOP AN IMMUNOASSAY FOR COCCIDIOIDES GALACTOMANNAN

    SBC: DXDISCOVERY INC            Topic: 86

    Giner’s innovation comprises of unique gene specific electrochemical detection that yields attomolar-level target DNA detection without nucleic acid amplification. The Phase I program will include: (1) Identification and selection of specific target gene sequences from Histoplasma and Coccidioides species followed by preparation of a DNA hybridization assay; (2) Electrochemical assay development ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government